Health Technology Assessment: Commission welcomes the adoption of new rules to improve access to innovative technologies
Yesterday evening, the Regulation on Health Technology Assessment (HTA), a deliverable of the EU Pharmaceutical Strategy, was adopted. The new rules will allow vital and innovative health technologies – such as innovative medicines, certain medical devices, medical equipment and prevention and treatment methods – to be more widely available. The Regulation will also ensure the efficient use of resources, strengthen the quality of HTA across the EU, and save national HTA bodies and industry from duplicating their efforts, reassure business and ensure the long-term sustainability of EU HTA cooperation. Welcoming the adoption, Commissioner for Health and Food Safety, Stella Kyriakides, made the following statement: “I am very pleased that today, after years of hard work, new rules to ensure that patients have better access to innovative medicines and medical devices will soon be a reality in the EU. The Regulation on Health Technology Assessment is a key deliverable of the European Pharmaceutical Strategy and an important building block for a European Health Union and our work to deliver concrete benefits to citizens in the area of health.” A press release with the full statement and Q&A are available online.
